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Available online 27 February 2013B-cell responses after infection or vaccination are often measured as serum titers of
antigen-specific antibodies. Since this does not address the aspect of memory B-cell activity,
it may not give a complete picture of the B-cell response. Analysis of memory B cells by ELISpot
is therefore an important complement to conventional serology. B-cell ELISpot was developed
more than 25 years ago and many assay protocols/reagents would benefit from optimization.
We therefore aimed at developing an optimized B-cell ELISpot for the analysis of
vaccine-induced human IgG-secreting memory B cells. A protocol was developed based on
new monoclonal antibodies to human IgG and biotin–avidin amplification to increase the
sensitivity. After comparison of various compounds commonly used to in vitro-activate
memory B cells for ELISpot analysis, the TLR agonist R848 plus Interleukin (IL)-2 was selected
as the most efficient activator combination. The new protocol was subsequently compared to
an established protocol, previously used in vaccine studies, based on polyclonal antibodies
without biotin avidin amplification and activation of memory B-cells using a mix of antigen,
CpG, IL-2 and IL-10. The new protocol displayed significantly better detection sensitivity,
shortened the incubation time needed for the activation of memory B cells and reduced the
amount of antigen required for the assay. The functionality of the new protocol was confirmed
by analyzing specific memory B cells to five different antigens, induced in a limited number of
subjects vaccinated against tetanus, diphtheria and pertussis. The limited number of subjects
did not allow for a direct comparison with other vaccine studies. Optimization of the B-cell
ELISpot will facilitate an improved analysis of IgG-secreting B cells in vaccine studies.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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B cells are important for the immunity against both
bacterial and viral infections (Ahmed and Gray, 1996). Two
major B-cell populations that contribute to the maintenance of
immunological memory are long-lived plasma cells and
memory B cells. The long-lived plasma cells reside primarily
in the bone marrow (McHeyzer-Williams and Ahmed, 1999;
Amanna and Slifka, 2010) and continuously secrete antibodies
that act rapidly on invading microbes. Memory B cells reside
primarily in peripheral lymphoid tissues and can, upon
re-encounter with the priming antigen, differentiate into
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response (McHeyzer-Williams and Ahmed, 1999). During
infection, or after vaccination, the body produces both
long-lived plasma cells and memory B cells that provide an
immunological memory.
Conventionally, B-cell responses are assessed by the sero-
logical measurement of specific antibodies, often expected to
correlate with protection (Plotkin, 2010). However, analysis
limited to the measurement of serum antibody levels by e.g.
ELISA can be misleading as it excludes the detection of the
memory B-cell pool. Memory B cells can exist in the absence of
detectable serum antibody levels (West and Calandra, 1996;
Bauer and Jilg, 2006) and their rapid differentiation and
antibody production may be of high relevance for a protective
humoral response. The combined use of methods for the
analysis of B cells and serum antibody levels may therefore
give a more complete picture of an individual's B-cell mediated
immune response.
The B-cell ELISpot was first described in 1983 (Czerkinsky
et al., 1983) and has proven to be an important method for
the detection of IgG-producing B cells. The assay has also
been further developed for the detection of antigen-specific
plasma blasts and memory B cells (Bernasconi et al., 2002;
Crotty et al., 2004; Bauer and Jilg, 2006; Vallerskog et al.,
2008; Buisman et al., 2009; Cao et al., 2010). Whereas active
plasma blasts, potentially present in the blood, can be
examined directly without in vitro activation in a B-cell
ELISpot, memory B cells require pre-stimulation in order to
differentiate into detectable ASC. Bernasconi et al. showed
that memory B cells differentiate after stimulation with an
antigen-independent polyclonal activator (Bernasconi et al.,
2002) and most protocols used include such an activator in
combination with other stimuli. Common polyclonal activa-
tors used are CpG (a Toll-like receptor [TLR] 9 agonist),
pokeweed mitogen (PWM) and Staphylococcus aureus Cowan
(SAC) often combined with CD40-ligand (CD40L) and/or
cytokines like interleukin (IL-) 2 and IL-10 (Crotty et al.,
2004; Buisman et al., 2009; Cao et al., 2010). Crotty et al., for
instance, developed a 6 day stimulation protocol using a
combination of PWM + CpG + SAC; many labs have subse-
quently adopted that protocol. In 2009, Pinna et al. evaluated
methods for the activation of memory B cells and found that a
6 day protocol using the TLR7/TLR8 agonist R848 plus IL-2
was more efficient compared to PWM, CpG and SAC (Pinna et
al., 2009). Another aspect of the B-cell ELISpot protocol is the
kinetics of the memory B-cell activation. Generally, cells are
pre-stimulated for 5–6 days prior to being added to the
ELISpot plate for the quantification of ASC (Crotty et al., 2004;
Buisman et al., 2009; Cao et al., 2010; Weiss et al., 2012). The
duration of the stimulation is likely to depend on the potency
of the activation. Also, the differences between using PBMC
and purified B cells can have an impact on the activating
potency. (Buisman et al., 2009).
In the present study, a new IgG-specific B-cell ELISpot
protocol utilizing R848 + IL-2 for the activation of memory
B cells and new monoclonal antibodies directed towards
IgG for detection was developed. The new protocol,
using a 72-hour pre-activation schedule, induced total
IgG memory B-cell activation more efficiently than other
various activator protocols including PWM + CpG + SAC.
In comparison with an already established protocol utilizingCpG + IL-2 + IL-10 + antigen for a 5-day pre-activation,
the new protocol yielded an increased detection sensitivity
of antigen-specific memory B cells. The new protocol
was subsequently used to assess vaccine-induced, antigen-
specific antibody responses against five different antigens
(diphtheria toxin [DT], tetanus toxoid [TTd], pertussis toxin
[PT], filamentous hemagglutinin [FHA] and pertactin [PRN]),
and it successfully detected specific memory B-cell and
plasma blast responses to all included antigens. However,
due to the limited number of subjects included in this study
no direct comparison with other vaccine studies was made.
Additional optimization of the new protocol included the
use of biotinylated anti-IgG or antigen for detection which
further reduced the amount of antigen required for the
analysis.
2. Materials and methods
2.1. Subjects
For the initial work on optimizing the B-cell ELISpot
protocol and the cross-comparison of protocols, cells were
obtained from anonymous buffy coats from healthy blood
donors (The Karolinska University Hospital, Solna, Sweden).
For the assessment of vaccine-induced responses, blood was
obtained from two different cohorts at different time points
after vaccination; informed consent was given by all subjects.
Cohort 1 consisted of four adults who were recruited for the
evaluation of the new protocol's functionality. These subjects
were given one dose of the combined tetanus diphtheria and
pertussis vaccine (COVAXIS® Td5ap, Sanofi Pasteur, North
York, ON, Canada), containing ≥20 IU TTd, ≥2 IU DT, 2.5 μg
PT, 5 μg FHA, 3 μg PRN and 3 μg fimbrial agglutinogens
2 + 3. Blood was drawn at days 0, 7, 14 and 28 as well as
3 months after vaccination, except for one subject for which
the 3-month sample is missing. Cohort 2 was used for the
comparison of the two protocols and consisted of eight
adolescents who participated in a phase IV Booster trial
conducted at the Swedish Institute for Communicable
Disease Control (EUDRACT no 2008-008195-13). Four of the
subjects were given the same booster dose as cohort 1 and
four subjects were given one dose of vaccine containing
≥20 IU TTd, ≥2 IU DT and 20 μg PT, (diTekiBooster DTPa1,
Statens Serum Institut, Copenhagen, Denmark). Blood was
drawn at day 0 (pre-vaccination sample) and between days
28–42 (post-vaccination sample).
2.2. Assay antigens
PT (lot 042) and FHA (lot 039) were obtained from
Kaketsuken (Kumamoto, Japan). PRN (lot 180805 RS) was
kindly provided by A.M. Buisman from RIVM (Bilthoven, the
Netherlands). TTd was obtained from Statens Serum Institut
(SSI) (Copenhagen, Denmark) and DT was from Statens
Bakteriologiska Laboratorium (SBL) (Solna, Sweden).
2.3. Puriﬁcation, cryopreservation and thawing of peripheral
blood mononuclear cells (PBMC)
For the initial protocol optimization studies, PBMC were
Ficoll-isolated from buffy coats and cryopreserved as
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of vaccine-induced responses, whole blood was collected in
BD Vacutainer® CPT tubes with sodium heparin (Becton
Dickinson, Franklin Lakes, NJ, USA) and separated according
to the manufacturer's instruction. Cryopreservation and
thawing were performed as previously described (Nilsson et
al., 2008) using a freezing medium with 90% Fetal Calf Serum
(FCS) (Gibco Invitrogen, Paisley, UK) and 10% Dimethyl
Sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA).2.4. Development and optimization of a new B-cell ELISpot
protocol
2.4.1. Generation of monoclonal antibodies to human IgG
Mouse hybridomas were generated against a mix of
human IgG1-4 subclasses (Sigma-Aldrich) and monoclonal
antibodies (mAbs) were identified by ELISA screening for
reactivity with IgG1-4 separately, as well as serum-derived
IgG; the lack of mAb reactivity with human IgA, IgM (Jackson
ImmunoResearch Laboratories Inc., Baltimore, PA, USA) and
IgE (Mabtech, Nacka Strand, Sweden) was also confirmed.
MAbs displaying comparable reactivity with all subclasses
and total IgG were evaluated as capture and biotinylated
detection reagents in ELISA using methods as described in
Zuber et al. (2005). The combination of two capture mAbs
(MT91/145) and two biotinylated detection mAbs (MT78/
145) was defined by ELISA as the optimal capture assay
displaying equal reactivity with all human IgG subclasses.
The functionality of the mAb reagents in B-cell ELISpot was
confirmed as described below.Fig. 1. Evaluation of activators for human memory B cells in the new IgG B-cell ELISp
were pre-activated using different activators as indicated. Following pre-activation
plate and the total number of IgG-secreting B cells (ASC; antibody-secreting cells
CpG + PWM + SAC and analysis after 24–96 h pre-activation. B) Comparison of
analysis of ASC as above. C) Comparison of B-cell activators either in different mixe
results are shown as ASC/5 × 104 PBMC (A & B) or as % ASC relative to pre-activati2.4.2. Assay
After thawing, PBMC were rested for 1 h in humidity at
37 °C, 5% CO2 and divided into stimulated or unstimulated
cells. To the stimulated cells, 1 μg/ml R848 (Mabtech) and
10 ng/ml recombinant human (rh)IL-2 (Mabtech) were
added. Cells were subsequently incubated in culture flasks
for three days at 37 °C, 5% CO2. During the optimization
evaluation, other incubation times and activators were used
as indicated elsewhere. Other activators evaluated, either
alone or in combinations, were 1 μg/ml pokeweed mitogen
(PWM) (Sigma Aldrich), 10 ng/ml rhIL-6 and rhIL-4
(PeproTech, Rocky Hill, NJ, USA), 1 μg/ml anti-CD40 mAbs
(Mabtech), 1 μg/ml B-cell activating factor (BAFF) (R&D
systems, Minneapolis, MN, USA), 10 ng/ml rhIL-10 (Merck,
Whitehouse station, NJ, USA), 1 μg/ml SAC (Sigma-Aldrich)
and 3 μg/ml CpG (Invivogen, San Diego, CA, USA) (see Fig. 1).
For the preparation of ELISpot plates, MAIPSWU10
Multiscreen filtration plates (Millipore, Billerica, MA, USA)
were pre-wetted with 70% ethanol for ≤1 min and washed
with sterile water. Coating antigens (TTd, DT, PT, FHA and
PRN) were diluted to 0.5 μg/well in sterile phosphate
buffered saline (PBS) (SVA, Uppsala, Sweden) and anti-IgG
coating mAbs were diluted to 10 μg/ml in PBS and added to
the plate. Wells used as blank controls were incubated with
PBS only. The plates were then incubated overnight (ON) or
≤72 h at 4 °C. The plates were washed five times with PBS
and blocked with RPMI-GlutaMAX™ supplemented with
10 mM HEPES and 50 μg/ml Penicillin–Streptomycin and
10% FCS (all from Gibco Invitrogen), referred to as “R10”, for
at least 30 min at room temperature (RT). After the 72 hour
pre-activation period cells were harvested and washed onceot protocol (see Section 2.4.2). PBMC (5 × 104 cells/well) from 5 individuals
for 24–96 h, the PBMC were incubated for an additional 24 h in the ELISpot
) was determined. A) Comparison of pre-activation using R848 + IL-2 and
pre-activation with R848 + IL-2, R848 alone or IL-2 alone, followed by the
s or used alone. Analysis by ELISpot was made after 72 h pre-incubation. The
on using R8480 + IL-2 (C).
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added to the plates in duplicates with 100 μl cell suspension/
well (for cell concentrations see paragraph 2.7). The
ELISpot plates were incubated ON in humidity at 37 °C, 5%
CO2. The cells were discarded and the plates were washed
with PBS (5 × 200 μl/well). Biotinylated anti-IgG detection
mAbs diluted to a concentration of 1 μg/ml in PBS
supplemented with 0.5% FCS were added to the plate wells
and incubated for 2 h at RT. The plates were washed with
PBS (5 × 200 μl/well) before Streptavidin conjugated with
Alkaline-Phosphatase (SA–ALP) (Mabtech) diluted 1/1000 in
PBS supplemented with 0.5% FCS was added and incubated
for 1 h at RT. Unbound conjugate was washed away with PBS
(5 × 200 μl/well). BCIP/NBT-plus substrate (Mabtech) was
filtered through a 0.45 μm-filter and 100 μl/well was added
to the wells and incubated for 7 min at RT. The reaction was
stopped by rinsing the plates with tap water. The plates were
then left to dry ON in darkness.
2.5. Established B-cell ELISpot protocol
The protocol usedwas originally described in 2009 (Buisman
et al., 2009) but was later modified for a European collaboration
project (Child Innovac). Antigen coating concentrations were
1.5 μg/well for PT and 0.7 μg/well for TTd, all antigens and the
coating antibodywere diluted in PBS.Major changes in the Child
Innovac protocol were as follows; Stimulation: The cultivation
medium consisted of AIM V medium (Gibco Invitrogen)
supplemented with 10% FCS without β-mercaptoethanol. Also,
0.01 μg/ml of each antigen included in the assay was added to
the stimulated aliquot. Coating of plate: The plates were pre-
wetted with 35% ethanol and incubated with antigen ON or
longer (b5 days).
2.6. Antigen-speciﬁc B-cell ELISpot utilizing biotinylated antigen
for detection
An alternative strategy for the detection of antigen-specific
IgG secreting B cells was also evaluated. The protocol is
identical to the new ELISpot protocol described above (see
Section 2.4.2) except for two steps. Firstly, instead of using
antigen for coating, wells were coated with capture mAbs.
Secondly, instead of using detection mAbs, a biotinylated
antigen was used for detection. For the biotinylation of
antigen, biotin ester (Surelink™ Chromophoric Biotin; VWR,
Stockholm, Sweden) dissolved in dimethylformamide (DMF)
to 20 mg/ml was added to DT or TTd in PBS (3–4 mg/ml) at a
10 times molar excess. The conjugates were incubated for 2 h
at 25 °C at 400 rpm. The biotinylated antigens were dialyzed
for 4 days against PBS at 4 °C using a 10 kDa cut off dialysis
tube.
2.7. Processing of data
All plates were analyzed using either a CTL reader
(Immunospot, Cleveland, OH, USA) or an AID reader (AID
Diagnostika GmbH, Strassberg, Germany). Since the vaccine
induced antigen-specific B-cell responses were expected to
vary at the selected time points, different concentrations of
PBMC were added to the wells in the ELISpot plate. The cell
concentrations selected had been evaluated earlier (data notshown) and the concentrations were as follows; days 0 and
28–42: 2 × 105 PBMC/well, days 7 and 14: 1 × 105 PBMC/
well, and month 3: 4 × 105 PBMC/well. All cells were added
in a two-fold serial titration; the wells with the lowest
concentration were only used if the highest concentration
yielded a too numerous amount of spots to count. As a
control for non-specific spots, unstimulated as well as
stimulated cells were added in duplicates to blanco wells.
Total IgG wells were used as a positive control for each
subject at each time point; if a sample generated low total
IgG responses, the sample was retested. Plasma blasts were
defined as ASC detected in the wells of unstimulated cells
after subtracting spots detected in the unstimulated blanco
wells. Memory B cells were defined as the number of ASC in
the wells with stimulated cells after the subtraction of plasma
blasts and spots detected in the stimulated blanco wells.
Antigen-specific plasma cell as well as memory B cell ASC
was adjusted to ASC/1 × 106 PBMC for statistical analysis and
should be considered as a relative number and not an
absolute number of antigen-specific B cells.
2.8. Statistical analysis
The Wilcoxon matched-pair signed rank test was used for
the comparison between time points. All the data were
considered non-parametric and p-values b0.05 were consid-
ered statistically significant. Statistical analyseswere performed
using GraphPad Prism (GraphPad Software Inc., San Diego, CA,
USA).
2.9. Ethics
Ethical approval was obtained from the Regional Ethical
Board in Stockholm (protocol 2009/1:1).
3. Results
3.1. Optimization of B-cell ELISpot reagents and protocol
A human IgG B-cell ELISpot assay based on new capture and
detection mAbs was evaluated. Pinna et al. had previously
established the R848 + IL-2 combination as the optimal B-cell
activator (Pinna et al., 2009) and the use of R848 + IL-2 for
the activation of memory B cells was assessed using a B-cell
ELISpot measuring the total number of IgG-secreting cells
after pre-activating PBMC for 1–4 days prior to incubating
them in ELISpot plates for another day. In comparison with
CpG + PWM + SAC stimulation, the R848 + IL-2 stimulation
was more efficient with an optimal response found using a
72 h pre-activation (Fig. 1A). Cross-titration of R848 and IL-2
concentrations showed that optimal activation was achieved
using 1 μg/ml of R848 and 10 ng/ml of IL-2 although both 5
times higher and 5 times lower concentrations of these
reagents could be used without any significant loss of
activation (data not shown). Activation by R848 alone had a
weaker effect than the combination of R848 and IL-2. IL-2, on
the other hand, had a very little activating capacity by itself,
under the conditions used (Fig. 1B).
Since PWM is used for B-cell activation in many B-cell
ELISpot protocols, we compared PWM together with a
number of different co-activators, with R848 + IL-2
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potency of R848 + IL-2. PWM activation in combination
with CpG, anti-CD40 mAbs, BAFF or IL-6 was comparable to
PWM activation alone (approximately 70% of the ASC
obtained with R848 + IL-2). PWM plus IL-10 gave even less
activation than PWM alone. The activator used in the
established protocol (CpG + IL-2 + IL-10) yielded even
lower results; approximately 50% of the ASC obtained with
R848 + IL-2 stimulation.
3.2. Comparison of new and established B-cell ELISpot protocols
for antigen-speciﬁc ASC
PBMC from the eight adolescents in cohort 2 were used to
compare the new protocol against an established protocol.Fig. 2. Comparison of a new optimized B-cell ELISpot protocol (see Section 2.
vaccine-induced antigen-specific antibody-secreting cells (ASC). Memory B-cell res
by the two protocols in parallel using PBMC from eight DTPa-boostered subjects. P
PBMC were sampled between day 28–42 days after vaccination. Differences be
antigen-specific ASC/106 PBMC. A representative well image from one subject for
tetanus and acellular pertussis vaccine.Samples were taken pre- and post-vaccination with DTP
vaccine (day 0 and days 28–42, respectively) and vaccine-
induced responses against PT and TTd were measured. With
the new protocol, coating concentrations of antigen could be
lowered for both PT and TTd (0.5 μg/well) without any loss of
sensitivity (Fig. 2) and thus resulted in a lower consumption of
antigen compared to the established protocol (PT 1.5 μg/well,
TTd 0.7 μg/well). Using the new protocol, a significant increase
of the TTd-specific ASC was found between pre- and
post-samples (Fig. 2). In contrast, no significant change in the
TTd response was found using the established protocol.
Regarding the response to PT, two subjects identified by the
new protocol (Fig. 2) had a detectable response in the
post-vaccination sample. One of these two subjects was also
detected by the established protocol, but at lower levels. In4.2) with a previously established protocol (see Section 2.5); analysis of
ponses against tetanus toxoid (TTd) and pertussis toxin (PT) were evaluated
re-vaccination PBMC were sampled before vaccination and post-vaccination
tween the two protocols are described in Table 1. Results are shown as
each antigen and method is shown below the diagrams. DTPa: Diphtheria,
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also employed a shorter pre-activation time of 72 h compared
to 120 h for the established protocol (see Table 1).Fig. 3. Comparison of the detection sensitivity using antibody reagents from
the new optimized B-cell ELISpot protocol (see Section 2.4.2) versus a
previously established protocol (see Section 2.5). PBMC from five healthy
donorswere pre-activatedwith R848 + IL-2 for 72 h followed by an overnight
incubation in the ELISpot plate (1 × 105 cells/well). Total IgG antibody-
secreting cells (ASC) were detected using the antibody reagents from the
new protocol (coating with anti-human IgG monoclonal antibody [mAb] and
detection with biotinylated anti-human IgG mAb + streptavidin–ALP) or the
established protocol (coating with anti-human IgG polyclonal antibody [pAb]
and detection with anti-human IgG pAb-ALP). Results are shown as the mean
number total IgG ASC per 1 × 105 cell.3.3. Comparison of the antibody-based detection systems in the
two protocols
To investigate parameters that, in addition to the use of
different activators, could explain the better detection
sensitivity of the new protocol versus the established
protocol, the antibody reagents used in the two protocols
were compared. The new protocol uses mAbs and the
detection of spots is amplified by the biotin–streptavidin
system whereas the established protocol uses polyclonal
antibodies (pAbs) and a one-step detection system, i.e. a
detection pAb directly conjugated to ALP. PBMC from five
healthy donors were stimulated with R848 + IL-2 and the
number of IgG-producing cells was enumerated using
antibodies from the two different protocols. The mAb-based
system detected higher numbers of IgG-producing cells in all
five subjects, compared to the pAb-based system (Fig. 3),
thus adding another parameter explaining the better sensi-
tivity of the new protocol.3.4. Measurement of antigen-speciﬁc B-cell responses by the
new protocol
After optimizing the new protocol, its functionality for the
detection of vaccine-induced antigen-specific B-cell re-
sponses was evaluated. PBMC samples from the four healthy
adults in cohort 1 vaccinated against pertussis, tetanus and
diphtheria were assessed for antigen-specific B-cell re-
sponses to PT, FHA, PRN, TTd and DT. Individual changes
over time, after vaccination, in the memory B-cell population
were observed (Fig. 4). The subjects' response to the different
antigens varied which is expected as the subjects differed in
age as well as with regard to previous vaccinations and
natural infections. They also differed in their peak response
time point and in the magnitude of the response. The
response was maintained over the 3-month test period
after vaccination but with decreasing levels over time.
Unstimulated cells also yielded detectable ASC, albeit fewer
than found in the pre-activated memory B cells. The
unstimulated ASC most likely represent active plasma blasts
in vivo-induced by the vaccination and were generally only
observed one to two weeks after vaccination.Table 1
The major differences between the two antigen-specific IgG ELISpot protocols.
New protocol Established protocol
B-cell activator R848 + IL-2 CpG + IL-2 +
IL-10 + antigen
Pre-incubation time 72 h 120 h
Coating concentrations PT & TTd: 0.5 μg/well PT: 1.5 μg/well
TTd: 0.7 μg/well
Detection system Biotinylated detection
mAb + streptavidin–ALP
ALP-conjugated
detection pAb
PT: pertussis toxin, TTd: tetanus toxoid, mAb: monoclonal antibody, pAb:
polyclonal antibody.3.5. Comparing the two detection systems of the new protocol;
coated antigen or biotinylated antigen
Yet another aspect of improving the new B-cell ELISpot
protocol by using biotinylated antigens for detection was
investigated. In the regular setup of the protocol, the antigen
was coated and the detection of ASC was achieved by a
biotinylated detection mAb. In the alternative protocol,
coating was done with capture mAbs and detection
was achieved with a biotinylated antigen. Pilot tests had
shown that coating with antigen required a concentration of
10 μg/ml, while only 1 μg/ml or even less was needed for
the alternative protocol (data not shown). Three of the
vaccinated adults from cohort 1 assays were tested using both
protocol variants for the measurement of activator-induced
ASC specific for TTd andDT. The results showednodifference in
spot detection even though the biotinylated detection system
uses a ten times less antigen (Fig. 5).
4. Discussion
The homeostasis of the memory B-cell population and its
contribution to the maintenance of humoral memory is still
enigmatic. Little is known about why some pathogens evoke
life-long memory whereas others evoke protection lasting
only a decade or less (Amanna et al., 2007; Amanna and
Slifka, 2010). It is known that circulating memory B cells are
responsible for the rapid and protective antibody response
seen after a re-encounter with a pathogen (Tangye and
Tarlinton, 2009). It is therefore important to be able to detect
these cells in order to evaluate the complete B-cell mediated
memory response. The B-cell ELISpot is a well established
method for the detection of memory B cells and has been
applied in studies on many pathogens and in vaccine studies.
Despite this, many protocols in use were developed long time
ago and may not yield an optimal performance. In this study
we developed new assay reagents and optimized the
protocol resulting in a more rapid and sensitive assay
compared to already established protocols. In addition, the
Fig. 4. Evaluation of vaccine-induced antigen-specific memory B-cell responses using the new B-cell ELISpot protocol (see Section 2.4.2). PBMC from four
DTPa-vaccinated subjects, obtained at weeks 0, 1, 2, 4 and 12, were either used without pre-activation or were pre-activated with R848 + IL-2 for 72 h. The
plates were coated with five different antigens (0.5 μg/well) and the cells were added to the plate over night. Antibody-secreting cells (ASC) were detected by
incubating the plate with biotinylated anti-IgG monoclonal antibody followed by streptavidin–ALP. Results are shown as antigen-specific ASC/106 PBMC over
time. White bars represent the detected memory B cells (after pre-activation); black bars on top of white represent detected plasma cells (without
pre-activation). In wells where the number of ASC was too numerous to count (TNTC), an estimated value is given. Note that the y-axis differs between graphs.
PT: pertussis toxin, FHA: filamentous hemagglutinin, PRN: pertactin, TTd: tetanus toxoid, DT: diphtheria toxin. DTPa: diphtheria, tetanus and acellular pertussis
vaccine.
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utilizing biotinylated antigen for detection makes it possible
to further reduce the amount of antigen needed.
In this study, antigen-specific responses are reported as
ASC/1 × 106 PBMC for memory B cells as well as for plasma
cells. Another common way to report antigen-specific
memory B-cell frequencies is as a percentage of total
IgG-producing B cells. A consensus on what denomination is
more representative has not yet been reached and both are
presently used. (Crotty et al., 2004; Cao et al., 2010).
Expressing the frequency of memory B cells as % of total IgG
ASC may have the advantage that it compensates for
expansion and proliferation of B cells during pre-activation.
However, the frequency of plasma cells detected without any
pre-activation cannot be determined by comparison to total
IgG ASC obtained after pre-stimulation.
The PWM + CpG + SAC pre-activation protocol for
memory B cells was defined as the optimal activator by
Crotty et al. (2004). In Pinna et al. (2009), the efficiency of
using R848 + IL-2 for the activation of memory B cells was
shown although it was not directly compared to the activator
used by Crotty et al. In this study we compared theR848 + IL-2 protocol to the activators used by Crotty and
found the latter less potent. Other combinations of PWM and
different co-activators were also found to be less potent.
However, IL-21 together with R848 was comparable to IL-2,
but did not further enhance the activation (data not shown).
Different activators were also analyzed for their capacity to
activate IgA- and IgM-secreting B cells using B-cell ELISpot as
read-out and also here R848 + IL-2 did prove to be
significantly better than PWM used in combination with
various co-activators; for the activation of IgE-secreting B
cells, R848 + IL-2 was, however, not efficient, and anti-CD40
mAb together with IL-4 proved to be the most efficient
activator combination (unpublished data). The pre-activation
time required for the optimal induction of IgG secreting cells
was also evaluated in this study. In contrast to Crotty et al.,
who found that the optimal pre-activation time was 6 days,
we found that using the R848 + IL-2 combination gave peak
responses after only 3 days. The R848 + IL-2 activation also
induced higher numbers of IgG producing cells in comparison
with PWM + CpG + SAC. This study did not include a
comparison of using purified B-cells versus PBMC with the
new protocol. Using purified B-cells could be beneficiary
Fig. 5. An alternative detection system by the new ELISpot protocol (see Section 2.6) for antigen-specific antibody-secreting cells (ASC) using a biotinylated
antigen. Plates were coated with either 0.5 μg/well of tetanus toxoid (TTd) and diphtheria toxin (DT) or 1.0 μg/well of anti-human IgG monoclonal antibody
(mAb). PBMC from three subjects were pre-activated using R848 + IL-2 and subsequently added to the plates and incubated overnight. In the first step for the
detection of ASC in wells coated with antigen, biotinylated anti-IgG mAb was used; in wells coated with anti-human IgG mAb, a biotinylated antigen was used. In
the second detection step, Streptavidin–ALP was added to all wells. A. Results are shown as antigen-specific ASC/106 with black lines representing detection with
biotinylated antigen and broken lines representing detection in wells with coated antigen. B. Representative well images from one subject at one time point
detected with the two detection systems for each antigen.
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increased (Buisman et al., 2009; Hendrikx et al., 2011). But
the relative frequency of ASC does not differ between purified
B-cells and PBMC (Buisman et al., 2009) and therefore this
comparison was not considered crucial for this study.
The new protocol was subsequently compared to a
previously established B-cell ELISpot protocol from a Euro-
pean collaboration project, Child Innovac; the established
protocol has been used in the studies of vaccine-induced
antigen-specific B-cell responses to Bordetella pertussis
antigens (Buisman et al., 2009). Despite that the amount
of antigen used for coating was lowered and the
pre-stimulation time was shortened in the new protocol, a
significant increase in the TTd response between pre- and
post-vaccination samples was found using the new protocol.
Such an increase could not be statistically proven using the
established protocol. The new protocol could detect two
responding subjects in PT; only one of them was detected, at
lower levels, by the established protocol. The reason why so
few subjects responded in PT is not known. One possible
explanation could be that the time point of the post-sample
missed the peak level of PT-specific ASC or that the subjects
did not develop any PT-specific response.
Several plausible explanations can be sought for the
higher sensitivity of the new protocol and most likely, it is a
result of multiple parameters. The pre-stimulation step is one
important determinant for the outcome of the assay. The CpGactivation used in the established protocol is well known.
However, there are arguments that CpG may not be optimal
for the activation of all B-cell subsets. In one study, CpG
stimulation was found to activate the IgM + CD27+ B-cell
population but not the IgM-CD27+ subset (Bekeredjian-Ding
et al., 2008); similar results were obtained by Capolunghi et al.
(2008). In contrast, Crotty et al. (2004) showed that the
addition of CpG to PWM + SAC mix increased the number of
detectable IgG + CD27 + ASC. Hence, the impact of CpG
activation on IgG-secreting cells is contradictory. However, as
we found that the R848 + IL-2 mix was a better B-cell
activator, we did not further investigate this aspect of
activation using CpG.
Also the antibodies used, as well as the enzymatic
detection systems, are likely to have an impact on the
detection sensitivity of the two protocols. The established
protocol uses pAbs with a detection system based on
enzyme-conjugated anti-IgG antibodies whereas the new
protocol uses mAbs and detection utilizing a biotinylated
anti-IgG mAb followed by streptavidin–enzyme conjugate.
Our results show that the amplified mAb detection system
increased the sensitivity compared to the detection with a
one-step pAb system. The reactivity of the mAbs in
combination with the enhanced detection signal obtained
with the biotin–avidin amplification (Nordstrom and Ferrua,
1992) thus contributes to the higher sensitivity obtained
with the new protocol. An additional benefit favoring the
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increased batch-to-batch reproducibility (Lipman et al.,
2005).
The new protocol was also evaluated for its functionality
using PBMC from four recently vaccinated subjects. The
subjects were tested for B-cell reactivity against five different
antigens included in the vaccine. High- and low-responding
subjects were found for all five antigens, demonstrating the
functionality of the protocol. Using unstimulated as well as
pre-activated PBMC, in vivo activated plasma blasts and
memory B cells, respectively, could be analyzed in parallel;
plasma blasts generally peaked at day 7 and memory B cells
at days 7–14, in line with previous findings (Pinna et al.,
2009).
In the new optimized protocol, the amount of antigen
required for coating could be reduced with up to two thirds
compared to the established protocol, thus reducing the
assay cost. Further reduction of the antigen required, without
any loss of detection sensitivity, was achieved by utilizing
biotinylated antigens as an alternative detection system. In a
previous B-cell ELISpot study, the use of biotinylated antigens
for detection not only reduced the antigen consumption but
also increased the detection sensitivity (Dosenovic et al.,
2009). Differences between how an antigen performs when
coated versus when it is used as a biotinylated detection
reagent is likely related to the chemical nature of each
antigen.
Of importance, but not addressed by this study, is the
inclusion of positive and negative controls to ensure the
quality of the method. In this study a positive equality control
was included; the subjects' total IgG response. IgG-switched
memory B cells constitute approximately 20% of all the
circulating B cells (Perez-Andres et al., 2010) and a positive
total IgG response should therefore be obtained for every
subject at each time point. The variability of the number of
total IgG ASC in the duplicate wells could also be used as an
intra-assay control. An inclusion of an inter-assay control will
strengthen the reliability of the method and give a more
robust quality assurance system. However, the focus of this
study was to establish and optimize the method and
therefore no quality validation has been done. This should
be further evaluated in future studies.
In conclusion, we have established a new protocol for
detecting memory B cells as well as in vivo activated plasma
blasts that has a shorter assay time, higher sensitivity and
requires less antigen compared to other established proto-
cols. This new and simplified procedure may facilitate and
improve the evaluation of B-cell responses seen after
vaccination and infection and can generally help in studies
aimed to clarify the participation and contribution of B cells
in the defense against pathogens.
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